Immunocore IMCR 深 沪
已收盘 10-30 16:00:00 美东时间
30.49
-0.780
-2.49%
华盛通- 最 高31.4399
- 今 开31.00
- 成交量 29.02万股
- 最 低 30.13
- 昨 收 31.27
- 总市值 15.70亿
- 52周最高 40.7147
- 市盈率 静 --
- 换手率 0.56%
- 52周最低 27.50
- 委 比 44.64%
- 总股本 5149.86万
- 历史最高 76.98
- 量 比 0.67
- 振 幅 4.19%
- 历史最低 18.43
- 每 手 1
- 风险率 2.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅101.01%！Stifel上调ORIC Pharmaceuticals目标价至18美元，维持"买入"评级
今日重点评级关注：Stifel：维持ORIC Pharmaceuticals"买入"评级，目标价从14美元升至18美元；花旗：维持Liberty Energy"买入"评级，目标价从27.5美元升至28美元
10-27 12:30
Immunocore Holdings收涨0.97%，成交额617.58万美元
10月27日，Immunocore Holdings（IMCR）收涨0.97%，报31.28美元，成交额617.58万美元，市值16.11亿美元。 行情数据 ...
10-27 05:33
HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $100 price target.
10-27 01:09
Immunocore Holdings收跌0.27%，成交额2745.92万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:36
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
Immunocore announces the first patient dosing in a Phase 1 trial of IMC-S118AI, its first tissue-specific autoimmune candidate, for HLA-A*02:01-positive patients with type 1 diabetes. IMC-S118AI is a bispecific molecule designed to protect beta cells under T cell attack by targeting preproinsulin peptide on beta cells and inhibiting autoreactive T cells. Preclinical data published in Science Advances showed its ability to selectively bind beta ce...
10-15 11:00
Immunocore Holdings Announces Achievement Of Target Patient Enrollment In TEBE-AM Clinical Trial; Topline Overall Survival Data Expected As Early As End Of 2026
Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced the...
09-14 19:01
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
Immunocore announced the achievement of target enrollment (540 patients) in the TEBE-AM Phase 3 clinical trial evaluating KIMMTRAK (tebentafusp) for previously treated advanced melanoma. The trial compares KIMMTRAK as monotherapy and in combination with pembrolizumab versus Investigator’s Choice. Overall survival data is expected by end of 2026. KIMMTRAK targets HLA-A*02:01-positive patients with limited treatment options post-PD1 therapy.
09-14 11:00
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
IN8bio announced the appointment of Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development. With over 20 years of experience in γδ T cell biology and T cell engagers (TCEs), Dr. Polyakova brings significant expertise in oncology, immunology, and cell therapies. She previously served as Chief Scientific Officer at LAVA Therapeutics and LIfT Biosciences, and was Scientific Founder and Head of Discovery at Adaptate Biotherapeutic...
09-09 12:00
美股大行评级 | 罗斯百货、迪尔股份获多家大行上调目标价；沃尔玛、Advance遭多家大行下调目标价
今日重点评级关注：摩根士丹利：维持Ultragenyx Pharmaceutical"超配"评级，目标价从67美元升至74美元；Truist Securities：维持Solid Biosciences"买入"评级，目标价从16美元升至20美元
08-24 16:40
JP Morgan Reinstates Overweight on Immunocore Holdings, Announces $50 Price Target
JP Morgan analyst Jessica Fye reinstates Immunocore Holdings (NASDAQ:IMCR) with a Overweight and announces $50 price target.
08-22 03:08
